Key result
Bosentan IV decreased systolic blood pressure and increased coronary diameter in patients with stable coronary artery disease.
Why the study?
Does the endothelin antagonist bosentan improve systemic and coronary hemodynamics in patients with stable coronary artery disease?
RCT (n=28)
Double-blind
randomized
Does the endothelin antagonist bosentan improve systemic and coronary hemodynamics in patients with stable coronary artery disease?
Acute administration of the endothelin antagonist bosentan induces epicardial coronary vasodilation in patients with stable CAD, demonstrating that endogenous endothelin exerts a baseline vasoconstrictor tone.
Answers are grounded in this paper and cite their sources.
Bosentan improves coronary hemodynamics in CAD; confirms endothelin’s role in tone and leaves open therapeutic potential.
BACKGROUND: Endothelin is a potent endothelium-derived vasoconstrictor peptide with proliferative properties. Elevated levels of the peptide occur in coronary artery disease; however, its pathophysiological role as a regulator of coronary tone and structure is uncertain. Endothelin-receptor antagonists are specific tools to clarify this issue and might be useful in the treatment of coronary artery disease. METHODS AND RESULTS: In a double-blind, placebo-controlled randomized study, we investigated the effects of the ETA/ETB endothelin-receptor antagonist bosentan or placebo on systemic and coronary hemodynamics in 28 patients with angiographically documented stable coronary artery disease by quantitative coronary angiography and an intracoronary Doppler guidewire. Bosentan 200 mg IV decreased systolic blood pressure (P<0. 05), whereas heart rate increased slightly (P<0.05). Coronary diameter increased, particularly in vessels with no or mild angiographic changes (P<0.01). Glycerol trinitrate did not further dilate these segments, whereas coronary diameter increased significantly after nitrate in the placebo group. The increase in coronary diameter after bosentan correlated inversely with plasma LDL-cholesterol levels (P<0.01) in both stenotic and angiographically normal coronary segments. Coronary flow velocity did not change. Bosentan was well tolerated. CONCLUSIONS: Endogenous endothelin exerts a vasoconstrictor tone in epicardial coronary arteries of patients with coronary artery disease, as evidenced by the vasodilation exerted by the combined ETA/ETB endothelin-receptor antagonist bosentan under acute conditions. Bosentan can safely be given to these patients. Hence, further long-term studies are necessary to determine the therapeutic potential of endothelin-receptor antagonists in patients with coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Wenzel et al. (1998) conducted an RCT in stable coronary artery disease (n=28). Bosentan vs. Placebo was evaluated on systemic and coronary hemodynamics. Bosentan IV decreased systolic blood pressure and increased coronary diameter in patients with stable coronary artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: